Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.52 |
| ▸ | PPARG | P37231 | 4/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28064101 | 0.96 | FFAR1 (0.52) | MAOBL3MBTL1MAPTKDM4EMEN1 | |
| SCHEMBL7908766 | 0.84 | SMN1; SMN2 (0.52) | KDM4EMEN1KMT2APPARGLMNA | |
| SCHEMBL687447 | 0.84 | SMN1; SMN2 (0.52) | KDM4EMEN1KMT2APPARGLMNA | |
| SCHEMBL7908936 | 0.84 | SMN1; SMN2 (0.52) | KDM4EMEN1KMT2APPARGLMNA | |
| SCHEMBL28064099 | 0.84 | FFAR1 (0.58) | MAOBNR4A1NR4A2NR4A3FFAR1 | |
| SCHEMBL2164933 | 0.82 | PPARG (0.58) | MAOBL3MBTL1MAPTKDM4EMEN1 | |
| SCHEMBL2164934 | 0.82 | PPARG (0.58) | MAOBL3MBTL1MAPTKDM4EMEN1 | |
| SCHEMBL5326113 | 0.81 | PPARG (0.59) | MAOBL3MBTL1MAPTKDM4EMEN1 | |
| SCHEMBL7099922 | 0.81 | PPARG (0.59) | MAOBL3MBTL1MAPTKDM4EMEN1 | |
| SCHEMBL2241052 | 0.80 | LDHA (0.49) | KDM4EFFAR1LMNAALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223881-B2 | Process for the preparation of new antidiabetic agents | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-05-29 | — | — | US | disclosed |
| US-20030125553-A1 | Process for the preparation of new antidiabetic agents | DR. REDDY'S LABORATORIES LIMITED | 2003-07-03 | — | — | US | disclosed |
| US-6531596-B1 | S(-)-2-methoxy-3-(4-(2-(phenoxazin-10-yl)methoxy) phenyl)propionic acid; benzylating p-hydroxybenzaldehyde or tyrosine; reaction with phenoxazinyl mesylate | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-03-11 | — | — | US | disclosed |
| EP-1124808-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF NEW ANTIDIABETIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026200-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF NEW ANTIDIABETIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125553-A1 | Process for the preparation of new antidiabetic agents | GLP1R, GPR119, SLC5A1 | MAOB 2027/4885L3MBTL1 4718/4885MAPT 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.